Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + obinutuzumab retreatment in relapsing CLL after prior fixed-duration Ven + anti-CD20
2023-504599-10-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Overall response rate in Cohort 1 at EOCT + 3 months and Overall response rate definition. Planned start Nov 2023; status: authorised.
02
Drugs
venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-504599-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504599-10-00.